Cargando…

Personalized Kampo Medicine Facilitated Both Cytotoxic T Lymphocyte Response and Clinical Benefits Induced by Personalized Peptide Vaccination for Advanced Esophageal Cancer

We retrospectively evaluated if personalized Kampo medicine (PKM) could facilitate CTL responses and clinical benefits induced by personalized peptide vaccination (PPV), in which HLA-matched vaccines were selected and administered based on the preexisting host immunity, for advanced esophageal cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muroya, Daisuke, Yutani, Shigeru, Shichijo, Shigeki, Yamada, Akira, Sakamoto, Shinjiro, Naito, Masayasu, Okuda, Koji, Morita, Michi, Yamaguchi, Rin, Itoh, Kyogo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5040795/ https://www.ncbi.nlm.nih.gov/pubmed/27703488 http://dx.doi.org/10.1155/2016/5929525

Ejemplares similares

Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies
por: Yutani, Shigeru, et al.
Publicado: (2017)

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer
por: Shirahama, Takahisa, et al.
Publicado: (2017)

Investigation of factors associated with reduced clinical benefits of personalized peptide vaccination for pancreatic cancer
por: Uchino, Yoshihiro, et al.
Publicado: (2021)

Identification of biomarkers for personalized peptide vaccination in 2,588 cancer patients
por: Suekane, Shigetaka, et al.
Publicado: (2020)

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients
por: Yutani, Shigeru, et al.
Publicado: (2015)

Personalized peptide vaccination as second‐line treatment for metastatic upper tract urothelial carcinoma
por: Suekane, Shigetaka, et al.
Publicado: (2017)

Immunological evaluation of peptide vaccination for cancer patients with the HLA ‐A11(+) or ‐A33(+) allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2017)

Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers
por: Noguchi, Masanori, et al.
Publicado: (2018)

Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
por: Sakamoto, Shinjiro, et al.
Publicado: (2015)

Elevation of Serum MAGE‐4 Protein Levels and Prediction of Hepatocellular Carcinogenesis in Patients with Liver Cirrhosis
por: Yutani, Shigeru, et al.
Publicado: (2002)

Juzentaihoto Failed to Augment Antigen-Specific Immunity but Prevented Deterioration of Patients' Conditions in Advanced Pancreatic Cancer under Personalized Peptide Vaccine
por: Yutani, Shigeru, et al.
Publicado: (2013)

Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte‐specific protein tyrosine kinase
por: Matsueda, Satoko, et al.
Publicado: (2018)

Plasma level of prostate related-antigen peptide-reactive IgG is a prognostic factor of patients with breast cancer treated with personalized peptide vaccines
por: Saku, Shuko, et al.
Publicado: (2021)

Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients
por: Iwasa, Satoru, et al.
Publicado: (2016)

Expression of the SART‐1 Antigens in Uterine Cancers
por: Matsumoto, Hajime, et al.
Publicado: (1998)

Immune responses of patients without cancer recurrence after a cancer vaccine over a long term
por: Suekane, Shigetaka, et al.
Publicado: (2022)

Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
por: Takahashi, Ryuji, et al.
Publicado: (2013)

Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2(+) cancer patients as cancer vaccine
por: Matsueda, Satoko, et al.
Publicado: (2015)

Induction of MAGE Genes in Lymphoid Cells by the Demethylating Agent 5‐Aza‐2′‐deoxycytidine
por: Shichijo, Shigeki, et al.
Publicado: (1996)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine
por: Koga, Noriko, et al.
Publicado: (2017)

Identification of Cyclophilin B‐derived Peptides Capable of Inducing Histocompatibility Leukocyte Antigen‐A2‐restricted and Tumor‐specific Cytotoxic T Lymphocytes
por: Tamura, Mayumi, et al.
Publicado: (2001)

Expression of Tumor‐rejection Antigens in Gynecologic Cancers
por: Tanaka, Shoko, et al.
Publicado: (2000)

Detection of MAGE‐4 Protein in the Sera of Patients with Hepatitis‐C Virus‐associated Hepatocellular Carcinoma and Liver Cirrhosis
por: Tsuzurahara, Shin‐ichi, et al.
Publicado: (1997)

Serine Proteinase Inhibitor 9 Can Be Recognized by Cytotoxic T Lymphocytes of Epithelial Cancer Patients
por: Tanaka, Koji, et al.
Publicado: (2002)

A Gene Encoding Antigenic Peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes
por: Shichijo, Shigeki, et al.
Publicado: (1998)

Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer
por: Toh, Uhi, et al.
Publicado: (2020)

Expression of MAGE‐1 Gene by Esophageal Carcinomas
por: Toh, Yuji, et al.
Publicado: (1995)

Development of Lobular Panniculitis Long After Completing the Personalized Peptide Vaccine Therapy
por: Uchida, Aira, et al.
Publicado: (2018)

CD8(+) tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER2‐positive ductal carcinoma in situ
por: Morita, Michi, et al.
Publicado: (2016)

Personalized peptide vaccination for cervical cancer patients who have received prior platinum-based chemotherapy
por: Kawano, Kouichiro, et al.
Publicado: (2015)

Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma
por: Rohde, Christoph, et al.
Publicado: (2019)

Sequence Analysis of Genes Encoding Rodent Homologues of the Human Tumor‐rejection Antigen SART‐1
por: Gotoh, Masashi, et al.
Publicado: (1998)

A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time
por: Noguchi, Masanori, et al.
Publicado: (2013)

The review of innovative integration of Kampo medicine and Western medicine as personalized medicine at the first multidisciplinary pain center in Japan
por: Arai, Young-Chang P, et al.
Publicado: (2014)

Evidence-based Reconstruction of Kampo Medicine: Part I—Is Kampo CAM?
por: Terasawa, Katsutoshi
Publicado: (2004)

PD-1 expression on peripheral blood T-cell subsets correlates with prognosis in non-small cell lung cancer
por: Waki, Kayoko, et al.
Publicado: (2014)

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial
por: Noguchi, Masanori, et al.
Publicado: (2020)

Prognostic implications of HER2 heterogeneity in gastric cancer
por: Motoshima, Shigenobu, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ll4fpg7g3eh1she0o0ns9i07q